Published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Abstract
Despite strong evidence linking amyloid beta (Aβ) to Alzheimer's disease, most clinical trials have shown no clinical efficacy for reasons that remain unclear. To understand why, we developed a quantitative systems pharmacology (QSP) model for seven therapeutics: aducanumab, crenezumab, solanezumab, bapineuzumab, elenbecestat, verubecestat, and semagacestat.
Authors
Kumpal Madrasi, Raibatak Das, Hafiz Mohmmadabdul, Lin Lin, Bradley T. Hyman, Douglas A. Lauffenburger, Mark W. Albers, Robert A. Rissman, John M. Burke, Joshua F. Apgar, Lucia Wille, Lore Gruenbaum, Fei Hua (2021)